News: The World Health Organization has granted prequalification to an additional Novel Oral Polio Vaccine Type 2 (nOPV2).
About Novel Oral Polio Vaccine Type 2 (nOPV2)
- It is an improved oral vaccine designed to prevent outbreaks caused by circulating vaccine-derived poliovirus type-2.
- The vaccine is used for active immunization in all age groups, especially during outbreaks of poliovirus type-2.
- Developed By: Global Polio Eradication Initiative
- Type: Live-attenuated oral vaccine targeting Polio type 2
- Aim of nOPV2
- To stop outbreaks of poliovirus type-2 in a safer and more effective way.
- To reduce the risk of vaccine-derived virus mutations.
- To strengthen global progress toward the eradication of polio.
- Key Features
- The vaccine is genetically more stable than the traditional monovalent oral polio vaccine type-2.
- The improved stability reduces the chance that the vaccine virus will mutate and cause new outbreaks.
- The vaccine provides strong intestinal immunity, which helps stop virus transmission quickly.
- It can be supplied in multi-dose vials (20- and 50-dose formats) suitable for high-volume vaccination programs.
- It has a shelf life of up to 24 months and can be kept at routine vaccine storage temperatures, facilitating use across a range of environments.
